Nuclear protein-1 (NUPR1) is a stress response factor that is important in the development of several human malignant tumor cells. However, the role of NUPR1 in multiple myeloma (MM) remains to be fully elucidated. In the present study, it was found that the mRNA levels of NUPR1 were significantly higher in specimens from patients with MM and MM cell lines (U266 and RPMI8226) than in cells of normal human bone marrow. The present study was undertaken to investigate the function of NUPR1 in the growth and apoptosis of MM cell lines. A lentivirus-mediated short hairpin RNA was used to specifically inhibit the mRNA and protein expression of NUPR1 in the U266 and RPMI8226 MM cell lines. Flow cytometry and Cell Counting Kit-8 assays were applied to examine the apoptosis and proliferation of U266 and RPMI8226 cell lines. The results revealed the inhibitory effect of NUPR1 silencing on the proliferation of U266 and RPMI8226 cells through inducing apoptosis, and arrest of cell cycle at the G 0 /G 1 phase. Furthermore, NUPR1 silencing caused activation of caspase-3, -8 and -9 and influenced specific gene expression, including an increase of phosphatase and tensin homolog (PTEN) and decrease of B-cell lymphoma 2 and proliferating cell nuclear antigen. These findings showed that NUPR1 may be involved in the proliferation and apoptosis of MM cells by adjusting caspase proteins and PTEN, suggesting that NUPR1 may be a novel therapeutic target for MM.
Introduction
Multiple myeloma (MM) is an incurable disease of hematological malignancies, characterized by the abnormal proliferation of plasma cells and overexpression of monoclonal immunoglobulin, which accounts for ~10% of hematopoietic neoplasias with increasing incidence worldwide. MM can be divided into hyperdiploid multiple myeloma (HD-MM) and non-HD-MM subtypes by fluorescence in situ hybridization (1) . The majority of cases of MM are from the original premalignant state, known as monoclonal gammopathy of undetermined significance, to smoldering MM, truly overt and symptomatic MM, and finally extramedullary MM/plasma cell leukemia (2, 3) . Despite agents, including proteasome inhibitors and immunomodulatory drugs, and rapidly developing stem cell transplantation technology, which have significantly improved the efficacy of treatment and prognosis of patients with MM, treatment for relapse remains limited.
Nuclear protein-1 (NUPR1), also known as p8 and candidate of metastasis 1, was first described in pancreatic acinar cells of rats when evaluating the molecular changes in the injured pancreas (4) . The NUPR1 gene is located on human chromosome 16p11.2. The length of its cDNA is 719 bp, and its open reading frame is 249 bp, encoding a protein with a molecular weight of 8,872.7 Da (5) . Studies have found that Nupr1 has a wide regulatory role in cell proliferation, migration and apoptosis, and is involved in the development of various types of tumor, including pancreatic cancer, liver cancer, bladder cancer and breast cancer (6) (7) (8) (9) . It has been shown that NUPR1 also regulates cell sensitivity to drugs in hepatocarcinoma cells (7) . It has been reported that there is a specific NUPR1 expression profile in HD-MM, which may become a novel drug target (10) . However, the characterization of its effects on MM cells remains to be fully elucidated.
In the present study, the effect of NUPR1 in MM cells was examined; it was found that NUPR1 was upregulated in MM cell lines (U266 and RPMI8226), and NUPR1 was then silenced using lentiviral short hairpin (sh)RNA in the U266 and RPMI8226 cells. The functional effect of NUPR1 was examined by proliferation, apoptosis and cell cycle assays. In order to examine the possible mechanism underlying these effects, the expression of genes known to be associated with proliferation and apoptosis were examined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analyses.
Materials and methods
Cell culture and sample collection. The U266 and RPMI8226 human MM cell lines were donated by Professor Jian Hou at The Second Military Medical University (Shanghai, China). The U266 and RPMI8226 cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) at 37˚C in a humidified incubator with 5% CO 2 . Bone marrow specimens were obtained from four patients with MM (two females and two males aged 77, 63, 75 and 61 years), and four healthy individuals (one female and three males aged 61, 65, 53 and 55 years) admitted to The First Affiliated Hospital of Chongqing Medical University (Chongqing, China). These specimens were collected between April 2016 and October 2016. The diagnosis was established according to standard morphological and immunophenotypic criteria and revised international staging system (11) . All specimens were obtained in accordance with the Research Ethics Board of the First Affiliated Hospital of Chongqing Medical University.
Lentiviral vector construction and cell infection.
The lentiviral shRNAs were designed and synthesized by Shanghai GeneChem Co., Ltd. (Shanghai, China). The RNA interference (RNAi) target sequence for NUPR1 was 5'-CCAAGCTG CAGAATTCAGA-3' whereas the control non-silencing RNA sequence was 5'-TTC TCC GAA CGT GTC ACG T-3'. The lentivirus was produced in 293T cells (American Type Culture Collection, Manassas, VA, USA) as discussed previously (12) . The U266 and RPMI8226 cells in the exponential phase were plated in 24-well plates (5x10 4 cells/well), infected with NUPR1-shRNA lentivirus or NC-shRNA lentivirus in the presence of 1 µg/ml polybrene at a set multiplicity of infection of 100. After 5 days, the transfection efficiency was estimated by flow cytometry.
RNA extraction and RT-qPCR analysis. Total RNA was extracted from cells with TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The RT reaction was performed using the Prime Script™ RT reagent kit according to the manufacturer's protocol (Takara Biotechnology Co., Ltd., Dalian, China). cDNA was reverse transcripted from 1,000 ng total RNA RT-qPCR analysis was performed using a CFX96 Real-Time PCR system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and a SYBR Premix Ex Taq™ II PCR kit (Takara Biotechnology Co., Ltd.). The primer pairs were as follows: NUPR1, forward 5'-AGG ACT TAT TCC CGC TGA CTG A-3' and reverse 5'-TGC CGT GCG TGT CTA TTT ATT G-3'; B-cell lymphoma 2 (Bcl-2), forward 5'-AAC ATC GCC CTG TGG ATG AC-3' and reverse 5'-GAC TTC ACT TGT GGC CCA GAT-3'; proliferating cell nuclear antigen (PCNA), forward 5'-CTC GTC CCA CGT CTC TTT GG-3' and reverse 5'-CGC GTT ATC TTC GGC CCT TA-3'; phosphatase and tensin homolog (PTEN), forward 5'-ACA CGA CGG GAA GAC AAG TT-3' and reverse 5'-CTG GTC CTG GTA TGA AGA ATG-3'; β-actin, used as an internal control, forward 5'-CCA CGA AAC TAC CTT CAA CTC C-3' and reverse 5'-GTG ATC TCC TTC TGC ATC CTG T-3'. The PCR reactions consisted of 30 sec at 95˚C, followed by 40 cycles at 95˚C for 5 sec and annealing at 60˚C for 30 sec. Relative gene expression was calculated using the 2 -ΔΔCq method (13) .
Western blot analysis. Total protein was extracted from the MM cells, and protein quantification was performed using the BCA method (Beyotime Institute of Biotechnology, Haimen, China). Subsequently, equal quantities of protein (40 µg) were separated by SDS-PAGE (12%), transferred onto PVDF membranes, and then blocked with 5% non-fat milk. The membranes and corresponding specific antibodies were incubated at 4˚C overnight. The following antibodies were used as primary antibodies: Rabbit anti-human NUPR1 antibody (1:1,000; cat. no. MBS420484; Novus Biologicals LLC, Littleton, CO, USA); PCNA (1:1,000; cat. no. ab18197; Abcam, Cambridge, UK) and PTEN (1:1,000; cat. no. ab31392; Abcam); cleaved caspase-3 (1:1,000; cat. no. Asp175; Cell Signaling Technology, Inc., Danvers, MA, USA,), cleaved caspase-8 (1:1,000; cat. no. Asp391; Cell Signaling Technology), cleaved caspase-9 (1:1,000; cat. no. Asp315; Cell Signaling Technology); Bcl-2 (1:800; cat. no. 12789-1-AP; ProteinTech Group, Inc., Wuhan, China); GAPDH (1:5,000; cat. no. 10494-1-AP; ProteinTech Group). These membranes were incubated with secondary antibodies (1:3,000; cat. no. 7074; Cell Signaling Technology) for 2 h at 37˚C, following washing with TBS-Tween-20 the following day. Excess antibody was removed with TBS-Tween-20 prior to incubation in ECL. The western blot assays were repeated three times. The band intensity was analyzed using Quantity One software (version 4.5.0; Bio-Rad Laboratories) according to the manufacturer's instructions.
Cell Counting Kit-8 (CCK-8) assay for cell proliferation. The proliferation of the U266 and RPMI8226 cells was evaluated following lentivirus infection for 5 days. The cells were resuspended and plated in 96-well plates at 2,000 cells per well. CCK-8 (10 µl; Dojindo Molecular Technologies, Inc., Kumamoto, Japan) reagent was added to each well, and the plates were incubated at 37˚C for 2 h. Cell growth was estimated by measuring the absorbance at 450 nm with a microplate reader (M88; Thermo Fisher Scientific, Inc.) at the end of incubation.
Cell cycle analysis by fluorescence-activated cell sorting (FACS). The cells were collected and centrifuged at 1,500 x g at 22˚C for 5 min. The cells were then washed with PBS, and fixed with cold 70% ethanol at 4˚C overnight. The cells were then stained with 50 µg/ml propidium iodide (PI) for 30 min at room temperature. Finally, each group of cells was determined using a FACScan cell sorter (BD Influx; BD Biosciences, Franklin Lakes, NJ, USA).
Assessment of apoptosis by flow cytometry.
The cells were collected and stained with annexin V-APC to differentiate intact cells from apoptotic cells. All cells were washed with ice-cold PBS twice and incubated for 30 min in a binding buffer (1 mg/ml annexin V-APC), respectively. FACS analysis for annexin V-APC staining was performed by flow cytometry using CellQuest software version 4.02 (BD Biosciences).
Statistical analysis. The differences between groups were analyzed using Student's t-test or one-way analysis of variance using SPSS 22 software (IBM Corp., Armonk, NY, USA). Data are expressed as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.
Results
Expression pattern of NUPR1 in human MM. The present study determined the mRNA expression of NUPR1 in U266 and RPMI8226 MM cell lines, and the specimens of patients with MM, with cells from normal human bone marrow as a control. As shown in Fig. 1 , the MM cell lines and MM patient specimens showed higher expression levels of NUPR1, compared with those in the normal bone marrow cells (P<0.05). Therefore, a specific lentiviral vector was designed to knock down the NUPR1 gene and examine the role of the gene in the U266 and RPMI8226 MM cell lines.
Downregulation of the expression of NUPR1 in U266 and RPMI8226 cell lines following lentivirus transfection.
To better understand the significance of the upregulation of NUPR1 in the MM cell lines, the lentivirus expressing shRNA against NUPR1 was used for gene silencing in the U266 and RPMI8226 cells. The transfection efficiency of the cells was detected using a fluorescence microscope ( Fig. 2A ) and flow cytometry (Fig. 2B) , the results of which showed that the transfection efficiency was >80%. The expression mRNA and protein levels of NUPR1 were determined by RT-qPCR and western blot analyses, respectively, following infection of the cells with the lentiviral vector (shCtrl or shNUPR1). The shNUPR1-transfected cells showed a significant reduction in mRNA and protein levels of NUPR1 when compared with the cells infected with the control lentivirus (Fig. 2C ).
Downregulation of NUPR1 suppresses cell growth in U266
and RPMI8226 cells. To examine the potential function of NUPR1 in the growth of U266 and RPMI8226 cells, CCK-8 assays were used to analyze cell proliferation. Following a 3-day period, the proliferation of cells in the NUPR1-shRNA group was significantly suppressed compared with those in the negative control group (Fig. 3 ).
Analysis of cell cycle and apoptosis.
Flow cytometry was performed to analyze apoptosis, as shown in Fig. 4A and B , the average apoptotic rates of the NUPR1-shRNA group and negative group U226 cells were 29.61±11.90 and 6.18±1.13%, and those of the RPMI8226 cells were 23.98±9.29 and 8.11±2.75%, respectively (P<0.05). This result revealed that knockdown of the expression of NUPR1 significantly promoted apoptosis of the U226 and RPMI8226 cells. FACS was used to examine the effect of NUPR1 knockdown on the cell cycle. As shown in Fig. 4C and D, compared with the negative group, the U266 and RPMI8226 cells in the NUPR1-shRNA group were arrested at the G 0 /G 1 phase (P<0.01).
Knockdown of NUPR1 affects the expression of apoptotic and proliferation proteins in U266 and RPMI8226 cells.
To investigate the molecular mechanism by which NUPR1 affects apoptosis and proliferation, the expression of relevant factors, including Bcl-2, cleaved caspase-3, -8 and -9, PTEN and PCNA, were examined in U266 and RPMI8226 cells with NUPR1 knockdown. The RT-qPCR and western blot analyses showed that the mRNA and protein levels of Bcl-2 and PCNA were significantly decreased in the NUPR1 shRNA-infected cells, whereas the expression level of PTEN was notably higher compared with that in the negative group. Western blot analysis revealed that the protein levels of cleaved caspase-3, -8 and -9 were higher in the U266 and RPMI8226 cells infected with the NUPR1-shRNA lentivirus, compared with those in the negative control group (Fig. 5A-C) .
Discussion
NUPR1 was originally identified from the rat pancreas during the acute phase of pancreatitis (5) . As a stress induced protein, it appears to be involved in a variety of stress-related functions and can produce different effects based on the physiological scenario. It is capable of promoting tumor growth and aggressiveness (14, 15) , however, the same molecule appears to have tumor suppressive activity in prostate cancer (16) , which depends on cancer cell type. This may be due to the different microenvironment affecting the activity of NUPR1. Previous studies have shown that NUPR1 affects the biological functions of tumor cells by regulating apoptosis and proliferation (17) (18) (19) . NUPR1 modulates the apoptosis and proliferation of glioblastoma cells via caspase activation and the extracellular signal-regulated kinase signaling pathway (20) . As an anti-apoptotic molecule, NUPR1 exerts an anti-apoptotic effect in breast cancer specimens and pancreatic cancer (8, 21, 22) .
However, whether and how NUPR1 affects MM cell viability remains to be fully elucidated, and few studies have been performed to determine the effects of NUPR1 on the behavior of MM cells in MM. In the present study, RT-qPCR was used to detect NUPR1 and it was found that the levels of NUPR1 in MM cell lines and specimens of patients with MM were significantly higher, compared with those in normal bone marrow cells. These results indicated that NUPR1 may be important in the progression of MM. The effects of NUPR1 on U266 and RPMI8226 MM cell line proliferation and apoptosis were also examined by infecting cells with an NUPR1-specific RNAi-expressing lentivirus. Apoptosis occurs in various physiological and pathological situations, and is involved in maintaining tissue homeostasis in multicellular organisms. Apoptosis may be initiated through different entry sites, including death receptors or mitochondria, which results in the activation of effector caspases (23, 24) . Resistance to apoptosis is one of the hallmarks of human cancer, and promotes the development and progression of cancer (25) . In addition, evasion from apoptosis represents one of the leading causes of failure of antileukemic therapy as numerous anticancer treatments act by triggering apoptosis in cancer cells (26) . The present study indicated that the NUPR1-shRNA-infected cells exhibited reduced cell proliferation and increased apoptosis, and FACS analysis demonstrated that the NUPR1-shRNA-infected U266 and RPMI8226 cells were arrested at the G 0 /G 1 phase, compared with the negative control group cells. Furthermore, the present study found that the knockdown of NUPR1 reduced the expression of PCNA and increased the expression of PTEN in U266 and RPMI8226 cells. PCNA is closely associated with cell DNA synthesis and repair, and promotes cell proliferation by increasing the synthesis of DNA polymerase (27) . Following the knocking down of NUPR1, the gene and protein levels of PCNA were significantly downregulated, indicating that downregulating NUPR1 inhibited the proliferation activity of cells, possibly by affecting DNA synthesis and repair in MM cells. PTEN has been identified as a tumor suppressor, and mutation of this gene may lead to the development of several types of cancer. It has been reported that PTEN can regulate proliferation and apoptosis in different types of cancer (28) (29) (30) (31) . Studies have show that via the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway, PTEN can regulate cell proliferation, and caspase-9 also regulated by Akt (32, 33) . As the activation of phosphorylated Akt can lead to the decrease of Bcl-2 and the increase of cleaved caspase-3 (34) , the present study examined the expression of Bcl-2, and cleaved caspase-3, -8 and -9, which are general apoptosis-related proteins. It was found that the knockdown of NUPR1 inhibited the expression of Bcl-2 and promoted the expression of cleaved caspase-3, -8 and -9, showing that inhibiting the expression of NUPR1 may directly or indirectly lead to the downregulation of Bcl-2 and activation of caspase-3, -8 and -9 via the PTEN/PI3K/AKT signaling pathway, which is responsible for the inhibition of U266 and RPMI8226 cell growth in vitro. However, for specific signaling pathways of NUPR1 in MM cells and its in vivo mechanisms, further investigations are required in subsequent experiments. Only a preliminary judgment can be made on the expression level of NUPR1 in patients with MM. In subsequent experiments, an increase in the number of specimens is required to analyze the expression of NUPR1, and its association with patient outcomes and prognosis.
In conclusion, the present study showed that lentivirus-mediated NUPR1-shRNA (RNAi targeting NUPR1) significantly inhibited the proliferation of U266 and RPMI8226 MM cell lines, and induced apoptosis in vitro. NUPR1 may be associated with the induction of apoptosis by activating caspases and increasing the expression of PTEN in U266 and RPMI8226 cells. Further investigation of the functional role of NUPR1 may lead to an improved understanding of the molecular mechanism of MM. Drugs suppressing the effects of NUPR1 and inducing apoptosis may be a valid strategy for the treatment of MM.
